Disease overview: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, with an inherent risk for leukemic transformation (15%-20% over 3-5 years).
tozoal infections (leishmaniasis); connective tissue disorders such as systemic lupus erythematosus and sarcoidosis, and lipid storage disorders. The recovery phase of an acute infection (usually viral) or bone marrow regeneration post chemotherapy is commonly associated with monocytosis. 13 Once these etiologies have been ruled out, molecularly defined clonal hematopoietic disorders need to be considered. First, chronic myeloid leukemia (CML) with the distinctive Philadelphia chromosome and the BCR-ABL1 fusion oncogene must be evaluated and excluded. 18 Rearrangement of the platelet-derived growth factor receptors A (PDGFRA) and B (PDGFRB) should then be evaluated for. PDGFRA (chromosome 4q12) and PDGFRB (chromosome 5q31-q32) are type III receptor tyrosine kinases. Chromosomal translocations involving PDGFRA/B have been associated with myeloid neoplasms characterized by prominent eosinophilia and responsiveness to imatinib. 19, 20 At times, PDGFR rearranged myeloid neoplasms can present with monocytosis and BM dysplasia, but given their unique responsiveness to imatinib, these are no longer classified as CMML. 21 Patients presenting with a clinical phenotype of CMML with eosinophilia, should be assessed for t(5;12)(q31-q32;p13), giving rise to the ETV6(TEL)-PDGFRB fusion oncogene. 21 The association between monocytosis and PDGFRA rearrangements is uncommon. 22, 23 Additional molecular markers that should be assessed for, in the context of monocytosis and eosinophilia include FGFR1 rearrangements and the PCM1-JAK2 fusion. 24 Monocytosis can be associated with MPN such as primary myelofibrosis and polycythemia vera, where its presence adversely impacts survival. 25, 26 The presence of a prior well documented diagnosis of a MPN, or MPNassociated driver mutations such as MPL and CALR, make the diagnosis of CMML less likely. 1 Finally, the presence of bone marrow dysplasia in at least one hematopoietic lineage should be established. If myelodysplasia is absent or minimal, a diagnosis of CMML can still be made if clonal cytogenetic or molecular abnormalities are present (discussed below). Table 1 lists the 2016 WHO recommended diagnostic criteria for CMML.
| Flow cytometry
Peripheral blood flow cytometry is a recent measure that has been used to help diagnose CMML. 27 Human monocytes can be divided into three subsets; CD14 The classical monocytes constitute majority of the human monocytes (85%) in healthy conditions. 28 27 In the abovementioned French study, the associated specificity and sensitivity values were reported at 95.1% and 91.9%
respectively. 27 Importantly, this repartition was noted to be independent of CMML mutational status and this increment corrected in CMML patients that responded to hypomethylating agents (HMA). 27 This technique has also been used to effectively distinguish monocytosis associated with CMML from monocytosis seen in patients with MPN, 29 and in identifying MDS patients with monocyte counts <1 3 10 9 /L who eventually develop CMML. 30 False negatives with this technique have been encountered in CMML patients with autoimmune diseases, where the M02 fraction increases, resulting in a false decrease in the M01 fraction. 30 We hope that by using additional monocyte markers such as CCR2, CD36, HLA-DR, and CD11c and better assessment techniques such as mass cytometry, we can improve upon the sensitivity and specificity of this assay. 31 
| Histopathology and immunohistochemistry
There is no single finding pathognomonic of the diagnosis of CMML.
Bone marrow biopsies are often hypercellular with granulocytic hyperplasia and dysplasia. Monocytic proliferation can be present, but is often difficult to appreciate and immunohistochemical studies that aid in the identification of monocytes and their precursors is recommended. 32 Almost 80% of patients will demonstrate micromegakaryocytes with abnormal nuclear contours and lobations, and 30% of patients can have an increase in BM reticulin fibrosis. 32 Twenty percent of patients can demonstrate nodules composed of mature plasmacytoid dendritic cells. The identification of promonocytes requires expertise and these cells are to be summated with blasts while estimating the blast count. 33 Promonocytes are described as monocytic where BM monocytosis is uncommon.
The diagnostic criteria for CMML place a heavy onus on the presence of PB monocytosis ( Figure 3 ). As discussed, monocytosis is associated with a variety of reactive and clonal causes. Persistent reactive monocytosis with marrow dysplasia can wrongly be labeled as CMML.
Similarly, CMML patients with progressive dysplasia or splenomegaly might develop peripheral blood cytopenias, and in spite of having FIG URE 1 Schematic approach to the differential diagnosis of peripheral blood monocytosis *: Peripheral blood abnormalities include unexplained anemia, thrombocytopenia, thrombocytosis, leukocytosis, eosinophilia, granulocytic dysplasia (pseudo Pelger Huët cells), circulating immature myeloid cells such as myelocytes, metamyelocytes and promyelocytes, promonocytes and blasts. **: FISH -fluorescence in-situ hybridization, PDGFRA and PDGFRB: Platelet-derived growth factor -A and Platelet-derived growth factor -B. FISH testing for PDGFRA and PDGFRB rearrangements is highly recommended if the peripheral blood monocytosis is associated with concomitant eosinophilia. The ETV6-PDGFRB fusion oncogene can give rise to clonal monocytosis mimicking CMML, but is in fact a unique molecularly defined myeloid neoplasm (not to be diagnosed as CMML). Similarly PDGFRA fusions are commonly associated with eosinophilia, but rarely can have associated monocytosis. Most PDGFRA fusions occur due to the karyotypically occult CHIC2 deletion (not detectable by metaphase cytogenetics) resulting in the FIP1L1-PDGFRA fusion oncogene. The World Health Organization also mandates FISH testing for FGFR1 rearrangements and the PCM1-JAK2 fusion, however, these abnormalities are very uncommonly associated with monocytosis. *** While estimating peripheral blood blasts in a patient with CMML, the blasts have to be summated with circulating promonocytes.
monocytosis, fail to meet the diagnostic criteria for CMML. Bone marrow monocytosis can be seen in patients with underlying dysplasia and while these patients may eventually progress to CMML, at this point, BM monocytosis is not incorporated into the diagnostic algorithm.
| Cytogenetic abnormalities in CMML
Clonal cytogenetic abnormalities are seen in 20%-30% of CMML patients. 5, [35] [36] [37] ; and (e) mutations in DNA damage response genes such as TP53 and PHF6. 54 The relative frequency of these mutations in individuals with CMML is shown in Table 2 . Of these, mutations involving TET2 (60%), SRSF2 (50%), ASXL1 (40%) and the oncogenic RAS pathway (30%) are most frequent, with only frame-shift and nonsense ASXL1 mutations independently and adversely impacting OS. 43, 55 The ASXL1 gene (chromosome 20q11) regulates chromatin by interacting with the polycomb-group repressive complex proteins (PRC1 and PRC2). 41 In a seminal paper, Abdel-Wahab et al. demonstrated that ASXL1 mutations resulted in loss of PRC2-mediated H3K27 (histone 3 lysine 27) tri-methylation. 56 In 4. < 20% blasts/blasts equivalent (promonocytes, monoblasts, and myeloblasts) in the peripheral blood and bone marrow.
5. Dysplasia in one or more myeloid cell lineages. If myelodysplasia is absent or minimal, the diagnosis of CMML may still be made if the other requirements are met and (see point 6)
6. An acquired clonal cytogenetic or molecular genetic abnormality (TET2, ASXL1, SRSF2, and SETBP1) is present in hemopoietic cells c .
a Myeloproliferative neoplasms (MPN) such as primary myelofibrosis and polycythemia vera can present with concurrent monocytosis. A previous documented history of MPN excludes a diagnosis of CMML. In addition, the presence of MPN like features in the bone marrow, or the presence of MPNassociated driver mutations, especially MPL and CALR make the diagnosis of CMML unlikely. b PDGFRA abnormalities most often involve the cryptic CHIC2 deletion at chromosome 4q12, resulting in the FIP1L1-PDGFRA fusion, commonly associated with peripheral blood eosinophilia and increased bone marrow mast cells. c While gene mutations involving TET2 (60%), SRSF2 (50%), ASXL1 (40%), and SETBP1 (15%) are common in CMML, they are not specific for the disease. TET2 and ASXL1 mutations can also be detected in patients with normal blood counts as a part of age related clonal hematopoiesis (clonal hematopoiesis of indeterminate potential). PDGFRB abnormalities most often involve the ETV6-PDGFRB gene fusion with 25 additional reported partners. This fusion is associated with peripheral blood monocytosis and concomitant eosinophilia. FGFR1 rearrangements often result in an aggressive stem cell leukemia/lymphoma syndrome characterized by MPN, eosinophilia and the development of T cell-acute lymphoblastic leukemia (ALL). The PCM1-JAK2 fusion usually results in eosinophilia with T-ALL or B-ALL.
impact either OS or LFS, ASXL1/EZH2 co-mutated patients have a shorter OS, in comparison to ASXL1mt patients alone. 58 The TET2 gene located on chromosome 4q24 is a member of the TET family of proteins. 59 TET2 has a dioxygenase enzymatic activity and converts 5-methyl-cytosine to 5-hydroxymethyl-cytosine (5hmC).
5hmC, represents a new base in genomic DNA, which may have a specific effect on transcription. 60, 61 Although TET2 mutations are widely prevalent in CMML (60%), they have not been shown to independently impact either OS or LFS. 43, 62 In a recent study, the presence of clonal TET2 mutations, in the absence of clonal ASXL1 mutations (ASXL1wt/TET2mut), had a favorable impact on OS. 63 The reason for this association is unclear. In MDS and younger patients with CMML (age <65years), the presence of clonal TET2 mutations, in the absence of clonal ASXL1 mutations, has been associated with response to HMA. 64, 65 Mutations involving TET1, TET3, and ASXL2 are extremely uncommon in CMML. 66 DNA methylation is mediated by a family of DNA methyltransferase enzymes (DNMT), including DNMT1, DNMT3A (chromosome 2p23), and DNMT3B. 67 DNMT1 primarily maintains pre-existing DNA methylation patterns, whereas DNMT3A and DNMT3B carry out de novo DNA methylation. 67 DNMT3A mutations are seen in 5% of CMML patients and independently and adversely impact both OS and LFS. 68 Of note, a recurrent Arginine882 (R882) hot spot accounts for 40%-60% of DNMT3A mutations, with limited data suggesting loss of methyltransferase activity in in vitro assays.
Spliceosome component mutations (SRSF2, SF3B1, U2AF1, PRPF8, and ZRSR2) affect pre-mRNA splicing. 5 SRSF2 mutations are common in CMML (50%) and are associated with increasing age, less pronounced anemia and a diploid karyotype. 5 Thus far, SRSF2 mutations have not demonstrated an independent prognostic impact on both, OS and LFS. 5, 43, 69 SF3B1 mutations have a high prevalence (80%) in patients with MDS and ring sideroblasts (RS) 70 and can also be seen in patients with CMML and RS (10%). 5 These mutations do not influence either the OS or LFS. 71, 72 Similarly, U2AF1 and ZRSR2 mutations are seen in 10% of CMML patients and have thus far lacked an independent prognostic effect. 73 Common signal pathway mutations in CMML include; oncogenic RAS pathway mutations (30%, NRAS, KRAS, CBL, and PTPN11), and and have been reported in 10-20% of patients with CMML. 43, 48 RUNX1 is essential for normal hematopoiesis and mutations can be seen in 10%-15% of patients with CMML. 43, 48 Although these mutations do not impact OS, there is a trend toward a higher risk for AML progression. 74 The sequence of genetic events leading to the clinical phenotype of CMML remains under investigation. It is thought that the initial driver mutation is likely to be a mutation in TET2 or ASXL1. This assumption is based on the high frequency of these mutations (40%-60%) in CMML, 75, 76 43 It should be noted that Table 3 highlights the CMML specific prognostic models along with their relevant components.
Seven clinical prognostic models, not incorporating ASXL1 mutational status (IPSS, R-IPSS, MDAPS, Global MDAPS, Dusseldorf, CPSS
and Mayo model) were statistically compared in a large dataset of CMML patients (n 5 1832). 80 All seven models were found to be valid with comparable performance, but were vulnerable to upstaging. 80 Rates of leukemic transformation vary among different series of CMML patients reported in the literature. However, most studies quote an incidence of 15%-20%. [86] [87] [88] In a study of 274 CMML patients followed for a median of 17.1 months, blast transformation (BT) occurred in 36 (13%). 17 On multivariable analysis, risk factors for BT were presence of PB blasts (HR 5.7; 95% CI 2.8-11.9) and female gender (HR 2.6; 95% CI 1.3-5.1); and the results remained unchanged when analysis was restricted to CMML-1. ASXL1/SRSF2/SETBP1 mutational frequencies were not significantly different between time of CMML diagnosis and BT. Median survival post-BT was 4.7 months (5-year survival 6%) and was better with allogeneic stem cell transplant (HCT) (14.3 months vs. 4.3 months for chemotherapy vs. 0.9 months for supportive care; P 5 .03). 17 
| R I SK A DA P TE D TH ER A P Y
After its inclusion as a specific category of myeloid neoplasms in the 2008 WHO classification, treatment options for CMML have evolved.
In the late 1990s, major treatment options consisted of chemotherapy such as etoposide, cytarabine, all-trans retinoic acid, [89] [90] [91] topotecan, 92,93 9-nitro-campothecin (topoisomerase inhibitor), 94 and lonafarnib (farnesyltransferase inhibitor). 95 Collectively, response rates in these trials were disappointing and therapy was associated with significant toxicities.
The United States Food and Drug Administration (FDA) approved two HMA, 5-azacitidine and decitabine, for treatment of patients with MDS. Two pivotal randomized studies that established the efficacy and safety of these drugs included a total of 361 patients with MDS. 96, 97 However, these studies only had 14 patients with CMML each, and the response rates for patients with CMML were not reported separately.
Since the publication of these studies, several Phase II studies have CMML. 105 This trial has currently been expanded to a phase II design and is currently accruing. Additional JAK/STAT inhibitors being preclinically assessed include momelotinib and pacritinib. 106 Given the inherent, demonstrable, GM-CSF (granulocyte-macrophage colony The CPSS-Mol used a genetic risk group stratification that assigned a score of 0 for low risk cytogenetics and absence of ASXL1/NRAS/SETBP1/RUNX1 mutations, a score of 1 for intermediate risk cytogenetics and mutations involving ASXL1/SETBP1 and NRAS, and a score of 2 for high risk cytogenetics and RUNX1 mutations. 
| Allogeneic stem cell transplantation
Allogeneic stem cell transplantation remains the only curative option for patients with CMML. This modality is however fraught with complications including, acute and chronic graft versus host disease (GVHD), nonrelapse mortality and post-transplant disease relapse. There unfortunately exists no prospective data analyzing the risks and benefits for HCT in CMML. The response rates in retrospective studies have ranged from 17% to 50%, with corresponding treatment related mortality rates ranging from 12% to 52% (Table 5) . [108] [109] [110] [111] [112] [113] [114] [115] The ten-year
OS of 85 patients who underwent HCT at Fred Hutchinson Cancer
Center was 40%. A multivariable model identified increasing age, higher
HCT comorbidity index and poor-risk cytogenetics to be associated with increased mortality and reduced relapse-free survival (RFS). to 2012 with a median age of 57 years and followed for a median of 51 months. 7 On multivariate analysis, CPSS score, Karnofsky performance status and graft source were significant predictors of OS.
In general, for younger patients with higher risk disease and an acceptable co-morbidity index, allogeneic HCT is the preferred treatment modality. 64 With the advent of reduced intensity conditioning and alternate donor sources (haploidentical HCT and double umbilical cord blood units), an increasing number of patients have access to HCT. While reduced intensity conditioning is associated with lower nonrelapse mortality, disease relapse rates are higher in comparison to myeloablative regimens. 116, 117 Similar to MDS, cytoreductive therapy or HMA are often considered prior to HCT in patients with increased BM blasts (CMML-2) or prior to a reduced intensity conditioning. 118 A recent retrospective study (n 5 83) demonstrated prior therapy with HMA followed by allogeneic HCT was associated with a lower cumulative incidence of relapse (22% versus 35%; P 5 .03), without a significant increase in the one-year transplant related mortality. 119 This finding needs prospective validation.
| Recommendations
Hydroxyurea Unfortunately, the response rates and survival following therapy is suboptimal, and therefore clinical trial participation is strongly encouraged.
The role of allogeneic HCT in CMML remains controversial. Similar to MDS, younger patients with an adverse survival, as determined by newer prognostic models incorporating molecular aberrations, should be considered for HCT. Older patients with a high HCT comorbidity index do not benefit from HCT, and are best suited for clinical trials. TR000136 from the National Center for Advancing Translational
